

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACEF1641

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 6 NOV 10 CA/CAPLUS F-Term thesaurus enhanced
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 8 NOV 20 CAS Registry Number crossover limit increased to 300,000 in
additional databases
NEWS 9 NOV 20 CA/CAPLUS to MARPAT accession number crossover limit increased
to 50,000
NEWS 10 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 11 DEC 11 CAS REGISTRY chemical nomenclature enhanced
NEWS 12 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 13 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and
functionality
NEWS 14 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 15 DEC 18 CA/CAPLUS patent kind codes updated
NEWS 16 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased
to 50,000
NEWS 17 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 18 DEC 27 CA/CAPLUS enhanced with more pre-1907 records
NEWS 19 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 20 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 21 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 22 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 23 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 24 JAN 22 CA/CAPLUS enhanced with patent applications from India

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

10/684,268

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:00:20 ON 24 JAN 2007

=> fil .bio

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'MEDLINE' ENTERED AT 14:01:28 ON 24 JAN 2007

FILE 'BIOSIS' ENTERED AT 14:01:28 ON 24 JAN 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 14:01:28 ON 24 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:01:28 ON 24 JAN 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> e monseaux s/au

E1	5	MONSEAU Y/AU
E2	1	MONSEAU YANNICK/AU
E3	4 -->	MONSEAU S/AU
E4	7	MONSEAU SYLVAIN/AU
E5	1	MONSEBAIZ DAVID/AU
E6	1	MONSEBAIZ F/AU
E7	1	MONSEBRAATEN L/AU
E8	1	MONSECH J/AU
E9	3	MONSECH JORGE/AU
E10	1	MONSECOUR DAVID/AU
E11	2	MONSECOUR KEVIN/AU
E12	22	MONSECOUR M/AU

=> s e3-e4

L1 11 ("MONSEAU S"/AU OR "MONSEAU SYLVAIN"/AU)

=> e montero julian f/au

E1	1	MONTERO JUAN JOSE/AU
E2	2	MONTERO JUAN PABLO/AU
E3	13 -->	MONTERO JULIAN F/AU
E4	59	MONTERO JULIAN F A/AU
E5	19	MONTERO JULIAN FELIX/AU
E6	37	MONTERO JULIAN FELIX A/AU
E7	1	MONTERO JULIAN FELIX ALEJANDRO/AU
E8	1	MONTERO JULIAN FIX A/AU
E9	1	MONTERO JULIAN G/AU
E10	2	MONTERO JULIAN GIL/AU
E11	2	MONTERO JULIO/AU
E12	4	MONTERO JULLIAN F/AU

=> s e3-e8

L2 130 ("MONTERO JULIAN F"/AU OR "MONTERO JULIAN F A"/AU OR "MONTERO JULIAN FELIX"/AU OR "MONTERO JULIAN FELIX A"/AU OR "MONTERO JULIAN FELIX ALEJANDRO"/AU OR "MONTERO JULIAN FIX A"/AU)

=> s e12

L3 4 "MONTERO JULLIAN F"/AU

=> s 11-13

L4 137 (L1 OR L2 OR L3)

=> s 14 AND (mhc? OR hla?)
L5 23 L4 AND (MHC? OR HLA?)

=> dup rem 15
PROCESSING COMPLETED FOR L5
L6 11 DUP REM L5 (12 DUPLICATES REMOVED)

=> d ibib ed abs 16 1-11

L6 ANSWER 1 OF 11 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2006466969 MEDLINE
DOCUMENT NUMBER: PubMed ID: 16761314
TITLE: Distinct orientation of the alloreactive monoclonal CD8 T cell activation program by three different peptide/MHC complexes.
AUTHOR: Auphan-Anezin Nathalie; Mazza Catherine; Guimezanes Annick; Barrett-Wilt Gregory A; Montero-Julian Felix; Roussel Alain; Hunt Donald F; Malissen Bernard; Schmitt-Verhulst Anne-Marie
CORPORATE SOURCE: Centre d'Immunologie de Marseille-Luminy, CNRS-INSERM-Universite de la Mediterranee, Campus de Luminy, Marseille, France.. auphan@ciml.univ-mrs.fr
SOURCE: European journal of immunology, (2006 Jul) Vol. 36, No. 7, pp. 1856-66.
Journal code: 1273201. ISSN: 0014-2980.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200609
ENTRY DATE: Entered STN: 8 Aug 2006
Last Updated on STN: 12 Sep 2006
Entered Medline: 11 Sep 2006

ED Entered STN: 8 Aug 2006
Last Updated on STN: 12 Sep 2006
Entered Medline: 11 Sep 2006

AB We have characterized three different programs of activation for alloreactive CD8 T cells expressing the BM3.3 TCR, their elicitation depending on the characteristics of the stimulating peptide/MHC complex. The high-affinity interaction between the TCR and the K(b)-associated endogenous peptide pBM1 (INFDFNTI) induced a complete differentiation program into effector cells correlated with sustained ERK activation. The K(bm8) variant elicited a partial activation program with delayed T cell proliferation, poor CTL activity and undetectable ERK phosphorylation; this resulted from a low-avidity interaction of TCR BM3.3 with a newly identified endogenous peptide, pBM8 (SQYYNSL). Interestingly, mismatched pBM1/K(bm8) complexes induced a split response in BM3.3 T cells, with total reconstitution of T cell proliferation but defective generation of CTL activity that was correlated with strong but shortened ERK phosphorylation. Crystal structures highlight the molecular basis for the higher stability of pBM8/K(bm8) compared to pBM1/K(bm8) complexes that exist in two conformers. This study illustrates the importance of the stability of both peptide/MHC and peptide/MHC-TCR interactions for induction of sustained signaling required to induce optimal CTL effector functions. Subtle allelic structural variations, amplified by peptide selection, may thus orient distinct outcomes of alloreactive TCR-based therapies.

L6 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:99520 CAPLUS
DOCUMENT NUMBER: 142:196532
TITLE: Methods for detecting activation of T-cells by MHC binding peptides
INVENTOR(S): Chang, Jennie Chyan Chuu; Kasey, Suha; Crebassa, Veronique Trigueros; Montero-Julian, Felix A.

PATENT ASSIGNEE(S): Beckman Coulter, Inc., USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005010026	A2	20050203	WO 2004-US23898	20040722
WO 2005010026	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

EP 1648919	A2	20060426	EP 2004-779108	20040722
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			

PRIORITY APPLN. INFO.:
US 2003-489359P P 20030722
WO 2004-US23898 W 20040722

ED Entered STN: 04 Feb 2005

AB The present invention is based on the discovery that MHC monomers immobilized to a solid surface are capable of activating T-cells that recognize specific peptides in the context of MHC class I or class II mols. Methods for detecting T-cells responding to MHC monomers, and methods for measuring the frequency of specific and activated T-cells in a heterogeneous population are provided. The present invention also provides systems and kits useful for conducting the methods of the present invention. In one example the inventors use MHC tetramers as reagent for both stimulating and staining to enumerate (1) total tetramer-pos. cells and (2) functional tetramer-pos. cells (e.g. cytokine-producing) incubated in the same tube. The results indicated that the presence of a high percentage of interferon γ -secreting cells detected in the tetramer-pos. population shows a very efficient stimulation of T cells by tetramers.

L6 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:394697 CAPLUS
DOCUMENT NUMBER: 142:445981
TITLE: Solution-based competition peptide exchange assay for quantifying the binding affinity of peptides of unknown binding properties for MHC heavy chain monomers or modified MHC monomers
INVENTOR(S): Montero-Julian, Felix A.; Monseaux, Sylvain; Necker, Antje
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 44 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005095655	A1	20050505	US 2004-782664	20040218
WO 2005047902	A1	20050526	WO 2004-US4910	20040218

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1692504 A1 20060823 EP 2004-712400 20040218

R: DE, FR, GB

PRIORITY APPLN. INFO.: US 2003-517019P P 20031103
 WO 2004-US4910 W 20040218

ED Entered STN: 09 May 2005

AB Disclosed are solution-based methods for identifying an MHC-binding peptide or measuring the affinity of MHC-binding peptides for an MHC monomer, or modified MHC monomer by incubating at least one MHC monomer or modified MHC monomer having bound thereto a template MHC-binding peptide, an excess amount of a competitor peptide, and a tracer MHC-binding peptide tagged with a detectable label (e.g. a fluorophore) to allow competition binding between the 3 peptides. The template peptide has lower or intermediate affinity as compared with the tracer peptide for the monomer. The MHC monomer (or modified MHC monomer) is biotinylated and the monomer is attached to the solid support via a biotin/avidin or streptavidin linkage. At least a portion of the competitor peptide exchanges with the template peptide and a difference in signal produced by the detectable label in the total sample as compared with signal produced solely by monomers after the competition assay is obtained and used to calculate affinity of the competitor peptide for the monomer. In the presented examples the monomer/peptide combination to be used as template for the peptide exchange assay was HLA-A*0201/Mart-1 26-35 and the selected tracer peptide was HLA-A*0201/HBVc-FITC. The competitor peptides were HIV pol, CMV pp65, HIV gag, and EBV Bmlf-1. These methods are useful in peptide discovery programs and exchanged monomers can be further tested for activity in tetramer cell staining assays.

L6 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:569762 CAPLUS

DOCUMENT NUMBER: 141:122328

TITLE: Microtiter plate- or bead-immobilized MHC I and II monomers for high throughput screening of MHC class I- and II-binding peptides

INVENTOR(S): Montero-Julian, Felix A.; Monseaux, Sylvain

PATENT ASSIGNEE(S): Beckman Coulter, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 269,473.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004137537	A1	20040715	US 2003-684268	20031010
US 2004072262	A1	20040415	US 2002-269473	20021011

PRIORITY APPLN. INFO.: US 2002-269473 A2 20021011

ED Entered STN: 16 Jul 2004

AB The invention is based on the discovery that MHC class I and class II monomers immobilized to a solid surface are still capable of forming complexes with suitable MHC-binding peptides. Methods

for detecting peptide binding to HLA monomers, and methods for measuring the relative degree of binding between two MHC-binding peptides as well as a method of measuring the rate of dissociation of peptides from MHC complexes are provided. The present invention also provides systems and kits useful for conducting the methods of the invention.

L6 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:310757 CAPLUS
 DOCUMENT NUMBER: 140:320022
 TITLE: Methods and systems for detecting MHC class I binding peptides
 INVENTOR(S): Montero-Julian, Felix A.; Monseaux, Sylvain
 PATENT ASSIGNEE(S): Fr.
 SOURCE: U.S. Pat. Appl. Publ., 33 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004072262	A1	20040415	US 2002-269473	20021011
CA 2501864	A1	20040422	CA 2003-2501864	20031010
WO 2004034033	A2	20040422	WO 2003-US32370	20031010
WO 2004034033	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003284113	A1	20040504	AU 2003-284113	20031010
US 2004137537	A1	20040715	US 2003-684268	20031010
EP 1549952	A2	20050706	EP 2003-776344	20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1703624	A	20051130	CN 2003-80101020	20031010
JP 2006502416	T	20060119	JP 2004-543745	20031010
PRIORITY APPLN. INFO.:			US 2002-269473	A 20021011
			WO 2003-US32370	W 20031010

ED Entered STN: 16 Apr 2004

AB The present invention is based on the discovery that MHC heavy chain monomers immobilized to a solid surface are still capable of forming detectable conformational epitopes and being detected by conformation-dependent antibodies. Methods for detecting peptide binding to HLA monomers, and methods for measuring the relative degree of binding between two MHC-binding peptides as well as a method of measurement for the rate of dissociation of peptides from MHC complexes are provided. The present invention also provides systems and kits useful for conducting the methods of the present invention.

L6 ANSWER 6 OF 11 MEDLINE on STN DUPLICATE 2
 ACCESSION NUMBER: 2004139082 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 14701802
 TITLE: Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells.
 AUTHOR: Kiessling Stephan; Muller-Newen Gerhard; Leeb Sandra N;

Hausmann Martin; Rath Heiko C; Strater Jorn; Spottl Tanja;
Schlottmann Klaus; Grossmann Johannes; Montero-Julian
F A; Scholmerich Jurgen; Andus Tilo; Buschauer Armin;
Heinrich Peter C; Rogler Gerhard

CORPORATE SOURCE: Department of Internal Medicine I, University of
Regensburg, Germany.

SOURCE: The Journal of biological chemistry, (2004 Mar 12) Vol.
279, No. 11, pp. 10304-15. Electronic Publication:
2003-12-29.
Journal code: 2985121R. ISSN: 0021-9258.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200405

ENTRY DATE: Entered STN: 23 Mar 2004
Last Updated on STN: 20 May 2004
Entered Medline: 19 May 2004

ED Entered STN: 23 Mar 2004
Last Updated on STN: 20 May 2004
Entered Medline: 19 May 2004

AB A tissue-protective effect of interleukin-11 (IL-11) for the intestinal
mucosa has been postulated from animal models of inflammatory bowel
disease (IBD). Despite the fact that the clinical usefulness of the
anti-inflammatory effects of this cytokine is presently investigated in
patients with IBD, there are no data available regarding the target cells
of IL-11 action and the mechanisms of tissue protection within the human
colonic mucosa. IL-11 responsiveness is restricted to cells that express
the interleukin-11 receptor alpha-chain (IL-11Ralpha) and an additional
signal-transducing subunit (gp130). In this study, we identified the
target cells for IL-11 within the human colon with a new IL-11Ralpha
monoclonal antibody and investigated the functional expression of the
receptor and downstream effects of IL-11-induced signaling.
Immunohistochemistry revealed expression of the IL-11Ralpha selectively on
colonic epithelial cells. HT-29 and colonic epithelial cells (CEC)
constitutively expressed IL-11Ralpha mRNA and protein. Co-expression of
the signal-transducing subunit gp130 was also demonstrated. IL-11 induced
signaling through triggering activation of the Jak-STAT pathway without
inducing anti-inflammatory or proliferative effects in colonic epithelial
cells. However, IL-11 stimulation resulted in a dose-dependent tyrosine
phosphorylation of Akt, a decreased activation of caspase-9, and a reduced
induction of apoptosis in cultured CEC. In HLA-B27 transgenic
rats treated with IL-11, a reduction of apoptotic cell numbers was found.
This study demonstrates functional expression of the IL-11Ralpha
restricted on CEC within the human colonic mucosa. IL-11 induced
signaling through triggering activation of the Jak-STAT pathway, without
inducing anti-inflammatory or proliferative effects. The beneficial
effects of IL-11 therapy are likely to be mediated by CEC via activation
of the Akt-survival pathway, mediating antiapoptotic effects to support
mucosal integrity.

L6 ANSWER 7 OF 11 MEDLINE on STN DUPLICATE 3

ACCESSION NUMBER: 2004448996 MEDLINE

DOCUMENT NUMBER: PubMed ID: 15155468

TITLE: OSCAR is an FcRgamma-associated receptor that is expressed
by myeloid cells and is involved in antigen presentation
and activation of human dendritic cells.

AUTHOR: Merck Estelle; Gaillard Claude; Gorman Daniel M;
Montero-Julian Felix; Durand Isabelle; Zurawski
Sandra M; Menetrier-Caux Christine; Carra Giuseppe;
Lebecque Serge; Trinchieri Giorgio; Bates Elizabeth E M

CORPORATE SOURCE: Laboratory for Immunological Research, Schering-Plough, 27
chemin des peupliers, BP11, 69571 Dardilly Cedex, France.

SOURCE: Blood, (2004 Sep 1) Vol. 104, No. 5, pp. 1386-95.
Electronic Publication: 2004-05-20.

Journal code: 7603509. ISSN: 0006-4971.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200410
ENTRY DATE: Entered STN: 11 Sep 2004
Last Updated on STN: 5 Oct 2004
Entered Medline: 4 Oct 2004

ED Entered STN: 11 Sep 2004
Last Updated on STN: 5 Oct 2004
Entered Medline: 4 Oct 2004

AB We have isolated a novel cell surface molecule, the human homolog of osteoclast-associated receptor (OSCAR). Unlike mouse OSCAR, hOSCAR is widely transcribed in cells of the myeloid lineage. Notably, hOSCAR is expressed on circulating blood monocytes and CD11c(+) dendritic cells but not on T and B cells. hOSCAR is continually expressed during differentiation of CD14(+) monocytes into dendritic cells and maintained after maturation. hOSCAR associates with the FcRgamma as shown by translocation of FcRgamma to the cell surface in presence of hOSCAR and coimmunoprecipitation from transfected cell lines and ex vivo cells. Engagement of hOSCAR with specific mAb leads to Ca(2+) mobilization and cytokine release, indicators of cellular activation. Endocytosis of the receptor in dendritic cells was observed, followed by passage of the internalized material into Lamp-1(+) and HLA-DR(+) compartments, suggesting a role in antigen uptake and presentation. Dendritic cells were able to stimulate a T-cell clone specific for an epitope of mouse IgG1 after uptake and processing of the hOSCAR-specific antibody, demonstrating the capacity of this receptor to mediate antigen presentation. hOSCAR thus represents a novel class of molecule expressed by dendritic cells involved in the initiation of the immune response.

L6 ANSWER 8 OF 11 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 2004273700 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15172452
TITLE: Use of a lentiviral vector encoding a HCMV-chimeric IEL1-pp65 protein for epitope identification in HLA -Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
AUTHOR: Rohrllich Pierre S; Cardinaud Sylvain; Lule Jacqueline; Montero-Julian Felix A; Prodhomme Virginie; Firat Huseyin; Davignon Jean-Luc; Perret Emmanuelle; Monseaux Sylvain; Necker Antje; Michelson Susan; Lemonnier Francois A; Charneau Pierre; Davrinche Christian
CORPORATE SOURCE: Antiviral Cellular Immunity Unit, Paris, France.
SOURCE: Human immunology, (2004 May) Vol. 65, No. 5, pp. 514-22.
Journal code: 8010936. ISSN: 0198-8859.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200503
ENTRY DATE: Entered STN: 3 Jun 2004
Last Updated on STN: 22 Mar 2005
Entered Medline: 21 Mar 2005

ED Entered STN: 3 Jun 2004
Last Updated on STN: 22 Mar 2005
Entered Medline: 21 Mar 2005

AB H2-deleted, HLA-A2, or HLA-B7 transgenic mice were used to identify new human cytomegalovirus (HCMV)-derived major histocompatibility complex class I-restricted epitopes. Three different approaches for mice immunization were compared for their ability to induce a cytotoxic CD8(+) T cell (CTL) response: (1). inoculation of infectious HCMV, (2). injection of immunogenic synthetic peptides, and (3). infection

with a newly designed HIV-derived central DNA flap positive lentiviral vector encoding the chimeric IE1-pp65 protein (Trip-IE1-pp65). Targets pulsed with either known immunogenic peptides or computer predicted ones were used to characterize CTL. Most of the mice immunized with the pp65 (495-NLVPMTATV-503) immunodominant peptide responded after one injection whereas only two of six mice responded to two successive inoculations with HCMV. Infection of mice with Trip-IE1-pp65 induced activation and expansion of CTL directed against peptides from both pp65 and IE1 and allowed identification of new epitopes. We further demonstrated the high capacity of monocyte-macrophage cells transduced with Trip-IE1-pp65 to activate and expand CTL directed against pp65 from peripheral blood mononuclear cells of HCMV-seropositive donors. Altogether these results suggest that Trip-IE1-pp65 is a powerful construct both to characterize new epitopes in combination with human leukocyte antigen-transgenic mice immunization and to provide an alternative to the use of known infectious and noninfectious approaches to expand effector T cells for adoptive immunotherapy.

L6 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:757210 CAPLUS
DOCUMENT NUMBER: 139:259944
TITLE: Immunoassays for beta2-microglobulin
INVENTOR(S): Montero-Julian, Felix A.; Necker, Antje
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003180811	A1	20030925	US 2002-96081	20020311
CA 2478699	A1	20030925	CA 2003-2478699	20030310
WO 2003079023	A1	20030925	WO 2003-US7611	20030310
W: AU, CA, JP				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
AU 2003213847	A1	20030929	AU 2003-213847	20030310
EP 1483586	A1	20041208	EP 2003-711541	20030310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
JP 2005520156	T	20050707	JP 2003-576977	20030310
PRIORITY APPLN. INFO.:			US 2002-96081	A 20020311
			WO 2003-US7611	W 20030310

ED Entered STN: 26 Sep 2003

AB Immunoassays useful for detecting free β 2-microglobulin in a sample containing β 2-microglobulin/ β 2-microglobulin associated protein complexes are provided. Also provided are a sandwich immunoassay and a competition immunoassay for detecting free β 2-microglobulin in a sample containing MHC monomers or MHC tetramers. Sandwich and competition ELISAs were used to measure the free β 2-microglobulin using HLA-A*0201/HIVgag, HLA-A*0201/HIVpol, and HLA-A*0201/Mart1 complexes. Kits for performing such immunoassays also are provided.

L6 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:896482 CAPLUS
DOCUMENT NUMBER: 139:363268
TITLE: Structural and kinetic basis for low affinity cross-reactivity in T cell allorecognition
AUTHOR(S): Guimezanes, Annick; Montero-julian, Felix; Schmitt-verhulst, Anne-marie
CORPORATE SOURCE: Centre d'Immunologie de Marseille-Luminy,

SOURCE: CNRS-INSERM-Univ. Mediterranee, Marseille, Fr.
European Journal of Immunology (2003), 33(11),
3060-3069
CODEN: EJIMAF; ISSN: 0014-2980
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 17 Nov 2003
AB The alloreactive BM3.3TCR interacts with high affinity with H-2Kb loaded with the endogenous peptide pBM1 (INFDFNTI), and shows low affinity cross-reactivity for H-2Kb loaded with a viral peptide VSV8 (RGYVYQGL), CTL activity requiring 103-fold higher peptide concentration and being highly sensitive to inhibition by anti-CD8 monoclonal antibody. VSV8 peptides substituted with pBM1/TCR contact residues (N6 and T7) retained low affinity characteristics and among pBM1 peptides substituted with residues Q6 and/or G7 present in VSV8, only pBM1(G7) was recognized, albeit with characteristics akin to those of VSV8. Despite the difference in KD values and the faster dissociation rate of multimeric VSV8/H-2Kb as compared to pBM1/H-2Kb complexes, similar TCR occupancy could be achieved with both multimers either at 4 or 37°. Only TCR engagement with pBM1/H-2Kb, however, resulted in early (Ca2+ flux) and late (CD69 expression) activation events in naive BM3.3TCR CD8 T cells. CD8 coreceptor, essential for binding of the weak agonists, was dispensable for binding of pBM1/H-2Kb multimers and their induction of signaling in naive T cells. Hence, high number of TCR and coreceptor engagement by weak agonists fail to substitute for strong agonist TCR engagement that can be coreceptor-independent and involve a limited number of TCR.
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 1994:372379 BIOSIS
DOCUMENT NUMBER: PREV199497385379
TITLE: Reliable flow cytometry HLA-B27 typing with B27-FITC/B7-PE combination.
AUTHOR(S): Zuber, C. [Reprint author]; Ulrich, G.; Monseaux, S. [Reprint author]; Cado, S.; Parmentier, S. [Reprint author]
CORPORATE SOURCE: IMMUNOTECH S.A., Marseille, France
SOURCE: Analytical Cellular Pathology, (1994) Vol. 6, No. 3, pp. 274.
Meeting Info.: Third Conference of the European Society for Analytical Cellular Pathology. Grenoble, France. May 16-20, 1994.
CODEN: ACPAER. ISSN: 0921-8912.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 31 Aug 1994
Last Updated on STN: 31 Aug 1994
ED Entered STN: 31 Aug 1994
Last Updated on STN: 31 Aug 1994

=> d his

(FILE 'HOME' ENTERED AT 14:00:20 ON 24 JAN 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 14:01:28 ON 24 JAN 2007

E MONSEAU S/AU
L1 11 S E3-E4
E MONTERO JULIAN F/AU
L2 130 S E3-E8
L3 4 S E12

L4 137 S L1-L3
L5 23 S L4 AND (MHC? OR HLA?)
L6 11 DUP REM L5 (12 DUPLICATES REMOVED)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

45.08

45.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

ENTRY

TOTAL

SESSION

CA SUBSCRIBER PRICE

-4.68

-4.68

STN INTERNATIONAL LOGOFF AT 14:03:08 ON 24 JAN 2007

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	8	("20030124513" "20050059107" "6413517" "6727093").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/24 13:55
S2	19	montero-julian-f\$.in. monseaux-s\$.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/24 10:51
S3	14	"6103493"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/24 12:32
S4	3	"20030073102"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/24 13:31
S5	2	"5635363".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/24 13:31
S6	297	(mhc hla) with (attach\$4 immobiliz\$5) with (support bead microtiter microtitre substrate surface nitrocellulose)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/24 13:56
S7	219	S6 and @ad<"20031010"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/24 13:57